期刊文献+

溴吡斯的明12h缓释片的体外释放行为相关性研究 被引量:2

Correlation between in vitro release of pyridostigmine bromide slow-release tablet and its in vivo pharmacokinetics
原文传递
导出
摘要 目的测定溴吡斯的明缓释片的体外释放和体内药代动力学,并研究其体内外相关性。方法按《中国药典》2010版二部附录XD释放度测定第二法,以磷酸缓冲液为释放介质,采用紫外分光光度法测定溴吡斯的明的累积释放百分率。6只新西兰兔采用自身交叉给药方案,单剂量口服溴吡斯的明缓释片和普通片后,采用HPLC-紫外色谱法测定不同时间点的体内血药浓度。结果溴吡斯的明缓释片12 h体外累积释放率达98.6%,其体内药动学参数如下:tmax为(4.001±0.004)h;Cmax为(15.442±0.215)mg/L;AUC0-∞为200.557±3.357。Loo-Riegelman法计算溴吡斯的明缓释片体内外的相关性,其体内累积吸收百分率与体外累积释放百分数X建立的线性回归方程为:fa=0.485 1 fr+3.837 7,r=0.986 5,大于临界值r6,0.01(P<0.01)。结论溴吡斯的明缓释片释放行为的体内外相关性显著,通过体外释放行为可预测其体内释放动力学。 Objective To study the correlation between in vitro release of pyridostigmine bromide slow-release tablet and its in vivo pharmacokinetics. Methods Accumulative release percentage of pyridostig- mine bromide slow-release tablet was assayed by ultraviolet spectroscopy with phosphate buffer as a dissolution medium according to the XD release assay in 2010 edition of Chinese Pharmacopeia. After 6 New Zealand rab- bits were given a single oral dose of pyridostigmine bromide slow-release or conventional tablet, their serum drug concentration was measured at different time points by HPLC-uhraviolet spectroscopy. Results The 12 h in vitro accumulative release rate of pyridostigmine bromide slow-release tablet was 98.6%. The main in vivo phar- macokinetic parameters for pyridostigmine bromide slow-release tablet were tmax : 4. 001± 0. 004 h , Cmax : 15. 442±0. 215 mg/L, and AUC0-∞ = 200. 557 ± 3. 357. The correlation between the in vitro release of pyri- dostigmine bromide slow-release tablet and its in vivo pharmacokinetics was assayed with the Loo-Riegelman method. The linear regression equation for the in vivo accumulative absorption percentage and the in vitro accu- mulative release percentage of pyridostigmine bromide slow-release tablets was fa = 0. 485 1 fr 3. 837 7, r = 0. 986 5, higher than the critical value r6 ,0. 01 (P 〈 0.01 ) . Conclusion The in vivo release of pyridostigmine bromide slow-release tablet is significantly correlated with its in vitro release. The in vitro release of pyridostig- mine bromide slow-release tablet can predict its in vivo pharmacokinetics.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第14期1411-1413,共3页 Journal of Third Military Medical University
基金 教育部博士点基金(20095503120008) 重庆市教育委员会资助项目(2009首批高等学校优秀人才资助)~~
关键词 溴吡斯的明 药代动力学 体内外相关性 pyridostigmine bromide pharmacokinetics in vitro-in vivo correlation
  • 相关文献

参考文献11

  • 1Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyri- dostigmine[J]. Clin Drug Investig, 2011, 31(10) : 691 -701.
  • 2Akbayram S, Akgun C, Dogan M, et al. Use of pyridoxine and pyri- dostigmine in children with vincristine-induced neuropathy[ J]. Indian J Pediatr, 2010, 77(6) : 681 -683.
  • 3Leong C F, Aini-Ardena M, Cheong S K, et al. Effect of pyridostig- mine (Mestinon) on human platelet aggregation[ J]. Malays J Pathol, 2009, 31(1): 45-52.
  • 4Seng K Y, Loke W K, Mooehhala S, et al. Retrospective population pharmacokinetie/pharmaeodynamic analysis of pyridostigmine, a eho- linesterase inhibitor, in Chinese males[J]. J Pharm Pharmacol, 2009, 61(9) : 1187 -1196.
  • 5谭群友,熊华蓉,王睿,李艺,张景勍.溴吡斯的明缓释片的药代动力学和相对生物利用度研究[J].第三军医大学学报,2011,33(5):511-514. 被引量:10
  • 6沈腾,郁韵秋,翁伟宇,李妮,黄照昌,蔡佳,黄建明.灯盏花素缓释片在兔体内的绝对生物利用度[J].中国临床药学杂志,2008,17(1):25-28. 被引量:13
  • 7吕雄文,李俊,金涌,张磊,葛金芳,王婷玉,彭磊.愈创木酚甘油醚缓释片在Beagle犬体内的药动学与生物利用度[J].中国医院药学杂志,2009,29(24):2071-2074. 被引量:3
  • 8Mandal A S, Chatterjee S, Kundu S, et al. In vitro-in vivo colTelation and bioavailability studies of captopril from novel controlled release do- nut shaped tablet[J]. Int J Pharm, 2011,421(1) : 145 -150.
  • 9United States Pharmacopeial Convention. In vitro and in vivo evaluation of dosage forms ( 1088 ) [ M ]//United States Pharmacopeia and Nation- al Formulary. Rockville : 21 ; United States Pharmacopeial Convention, Inc. 2007.
  • 10Welling P G, Tsee F L S, Dighe S V. Pharmaceutical bioequivalence [ J]. Marcel Dekker, 2006, 48: 223- 231.

二级参考文献26

  • 1蒋学华,李素华,兰轲,杨俊毅,周静.灯盏花素在家犬体内的药代动力学[J].药学学报,2003,38(5):371-373. 被引量:67
  • 2刘奕明,林爱华,陈汇,曾繁典.灯盏乙素在兔体内药代动力学(英文)[J].药学学报,2003,38(10):775-778. 被引量:31
  • 3刘欢,只德广,高晶,刘昌孝,王春龙.复方愈麻美芬缓释片在Beagle犬体内的药物动力学研究[J].沈阳药科大学学报,2004,21(5):328-332. 被引量:9
  • 4徐庆有,李学信.灯盏细辛注射液对高粘滞血症病人血液粘度的影响[J].新药与临床,1995,14(4):233-234. 被引量:77
  • 5Wanger D L,Patel V S. Steady-state human pharmacokineties and bioavailability of guaifenesin and pseudoepherine in a sustained-release tablet relative to immediate-release liquids[J]. Int J Pharm,1995,114(2):171-176.
  • 6Frick C G, Helming M, Martyn J A, et al. Continuous administration of pyridostigmine improves immobilization-induced neuromuscular weakness[J]. CritCareMed, 2010, 38(3): 922-927.
  • 7Akbayram S, Akgun C, Dogan M, et al. Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy[ Jl. Indian J Pediatr, 2010, 77(6): 681 -683.
  • 8Leong C F, Aini-Ardena M, Cheong S K, et al. Effect of pyridostigmine (Mestinon) on human platelet aggregation[ J]. Malays J Pathol, 2009, 31(1) : 45 -52.
  • 9Siepmann J, Peppas N A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose ( HPMC ) [ J ]. Adv Drug Deliv Rev,2001, 48(2/3) : 139 - 157.
  • 10De Ruyter M G, Cronnelly R. Reversed-phase, ion-pair liquid chromatography of quaternary ammonium compounds: determination of pyridostigmine, neostigmine and edrophionium in biological fluids [ J ]. J Chromatogr, 1980, 183(2): 193-201.

共引文献22

同被引文献13

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部